Aegis Capital Corp. Acted as Sole Bookrunner on a $12.1 Million Follow-On Offering for BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV)

February 3, 2021 2:46 PM EST
Get Alerts BVXV Hot Sheet
Price: $3.50 -0.85%

Overall Analyst Rating:
    BUY (= Flat)

Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

NEW YORK, NY / ACCESSWIRE / February 3, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $12.1 Million Follow-On Offering for BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses. The Company had been developing M-001, a novel influenza vaccine candidate that was designed to provide multi-strain and multi-season protection against current and future, seasonal and pandemic influenza. In seven Phase 1/2 and Phase 2 clinical trials designed to test for immunogenicity, the Company was able to demonstrate M-001 was effective in stimulating an immune response to a broad range of influenza virus strains. In October 2020, the Company completed a Phase 3 clinical trial of M-001 which failed to meet the trial's primary and secondary efficacy endpoints. The Company is now pursuing opportunities in the infectious disease space, including exploring several alternatives for development of a pipeline of assets.

About Aegis Capital Corp.

Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research and sales and trading services to institutional investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services.

For more information about this offering or Investment Banking Services please email InvestmentBanking@aegiscap.com or call (212) 813-1010

www.aegiscapcorp.com

This communication has been prepared by Aegis Capital Corporation for distribution to Aegis Capital Corporation's clientele. This communication is not intended for public dissemination and the recipient is prohibited from sharing this information. This communication has been prepared for institutional - accounts, as defined within FINRA Rule 4512(c), who (1) are capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities; and (2) will exercise independent judgment in evaluating the recommendations of any broker - dealer or its associated persons. This communication is not a product of Aegis Capital Corporation Research Department. Aegis Capital Corporation., Member FINRA, SIPC

SOURCE: Aegis Capital Corp.



View source version on accesswire.com:
https://www.accesswire.com/627766/Aegis-Capital-Corp-Acted-as-Sole-Bookrunner-on-a-121-Million-Follow-On-Offering-for-BiondVax-Pharmaceuticals-Ltd-NasdaqBVXV



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Accesswire, Press Releases